Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain
Evaluation of the Efficacy and Safety of Transdermal Fentanyl in Patients Suffering From Chronic Cancer Pain in an Ambulatory Setting
Sponsor: Janssen Cilag S.A.S.
Terminated
Sponsor discontinued the study following the discovery of a number of incompletely sealed batches that were unusable.
Other terminated trials from Janssen Cilag S.A.S.
More terminations from Janssen Cilag S.A.S.
Listed as NCT00236327, this PHASE4 trial focuses on Pain and remains terminated or withdrawn. Sponsored by Janssen Cilag S.A.S., it has been updated 9 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE4
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE4
First recorded
Jun 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Cilag S.A.S.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.